Just to be clear on Michael Frazis, his fund participated in the recent equity raising so he has a vested interest in the business. He conducted a soft ball interview with the CEO here:

https://podcasts.apple.com/au/podcast/79-repairing-nerves-with-orthocell-ceo-paul-anderson/id1451246735?i=1000680609156

Although it was clearly an opportunity to promote the business, I have to say the parallels with Polynovo did appeal to me.

One thing I found a little odd (I think just my ignorance) was the approvals process. Remplir apparently required human clinical trials for approval in Australia but not in the US, but then the discussion was around the animal trials needed for approval in the US? Odd. Anyway I'll do some reading. The CEO was very positive around chances of FDA approval.